Literature DB >> 31038718

Hypersensitivity pneumonitis recognised in a single pulmonary unit, between 2005 and 2015 - comparison with recently proposed diagnostic criteria.

Monika Szturmowicz1, Inga Barańska2, Małgorzata Ewa Jędrych3, Iwona Bartoszuk3, Piotr Radwan-Roehrenschef3, Adriana Roży4, Iwona Bestry2, Joanna Chorostowska-Wynimko4, Renata Langfort5, Jan Kuś3.   

Abstract

INTRODUCTION: Hypersensitivity pneumonitis (HP) is the third most common interstitial lung disease after idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Pathogenesis of HP is related to repeated exposure to inhaled environmental antigens that sensitise the susceptible, genetically predisposed persons. The aim of the present retrospective study was to summarise the diagnostic methods used in consecutive patients with HP, recognised in a single pulmonary unit, between 2005 and 2015, and to compare them with current diagnostic criteria.
MATERIAL AND METHODS: 135 patients, 68 males, 67 females, median age 53 years (18-75 years), entered the study. Chest CT features characteristic of HP were defined as: mosaic attenuation of lung parenchyma, air trapping and/or ill-defined centrilobular nodules. Lymphocytosis in BAL was defined as ≥ 30%.
RESULTS: Median time from first symptoms to diagnosis was 12 months. The exposure to one or more allergens was found in 94% of patients, chest CT features characteristic of HP have been reported in 87%, BAL lymphocytosis - in 86%. According to recent diagnostic criteria - in 54% of patients, clinical diagnosis of HP was confident, in 16% - probable, in 26% - possible and in 4% - unlikely. The confirmation of HP with lung biopsy has been obtained in 36% of non-confident cases (16% of the study group).
CONCLUSION: HP diagnosis was confirmed according to current diagnostic criteria in 70% of patients diagnosed between 2005 and 2015. Contradictions to lung biopsy have been the main reason for inability to confirm HP in non-confident cases.

Entities:  

Keywords:  bronchoalveolar lavage; diagnostic criteria; high resolution chest computed tomography; hypersensitivity pneumonitis

Mesh:

Substances:

Year:  2019        PMID: 31038718     DOI: 10.5603/ARM.2019.0014

Source DB:  PubMed          Journal:  Adv Respir Med        ISSN: 2451-4934


  5 in total

1.  Echocardiographic signs of pulmonary hypertension in patients with newly recognized hypersensitivity pneumonitis, prevalence and clinical predictors.

Authors:  Małgorzata Dybowska; Inga Barańska; Monika Franczuk; Agnieszka Skoczylas; Monika Szturmowicz
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

2.  Identifying causation in hypersensitivity pneumonitis: a British perspective.

Authors:  Christopher Michael Barber; P Sherwood Burge; Jo R Feary; Helen Parfrey; Elizabeth A Renzoni; Lisa G Spencer; Gareth I Walters; Ruth E Wiggans
Journal:  BMJ Open Respir Res       Date:  2019-12-03

3.  Correlation of bronchoalveolar lavage lymphocyte count with the extent of lung fibrosis and with plethysmographic lung volumes in patients with newly recognized hypersensitivity pneumonitis.

Authors:  Monika Szturmowicz; Inga BaraŃska; Agnieszka Skoczylas; MaŁgorzata E JĘdrych; Urszula Demkow
Journal:  Cent Eur J Immunol       Date:  2020-11-01       Impact factor: 2.085

4.  Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: a retrospective cohort study.

Authors:  Małgorzata Sobiecka; Monika Szturmowicz; Katarzyna Lewandowska; Agata Kowalik; Ewa Łyżwa; Katarzyna Zimna; Inga Barańska; Lilia Jakubowska; Jan Kuś; Renata Langfort; Witold Tomkowski
Journal:  BMC Pulm Med       Date:  2021-12-17       Impact factor: 3.317

5.  The value of serum precipitins against specific antigens in patients diagnosed with hypersensitivity pneumonitis - retrospective study.

Authors:  Monika Szturmowicz; Barbara Garczewska; Małgorzata E Jędrych; Iwona Bartoszuk; Małgorzata Sobiecka; Witold Tomkowski; Ewa Augustynowicz-Kopeć
Journal:  Cent Eur J Immunol       Date:  2020-01-20       Impact factor: 2.085

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.